916902-55-1

Basic information

• Product Name: 6-Hydroxymethyl-1H-indazole
• Synonyms: 6-Hydroxymethyl-1H-indazole;1H-INDAZOLE-6-METHANOL;(1H-indazol-6-yl)methanol;(1H-pyrazolo[3,4-b]pyridin-6-yl)methanol;(1H-Indazol-6-yl)
• CAS NO: 916902-55-1
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.164
• Product Categories: Building Blocks;Indazole
• Mol File: 916902-55-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 159 °C
• Boiling Point: 380.3 °C at 760 mmHg
• Flash Point: 183.8 °C
• Appearance: /
• Density: 1.36 g/cm³
• Vapor Pressure: 1.84E-06mmHg at 25°C
• Refractive Index: 1.721
• Storage Temp.: 2-8°C
• PKA: 13.92±0.40(Predicted)
• CAS DataBase Reference: 6-Hydroxymethyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxymethyl-1H-indazole(916902-55-1)
• EPA Substance Registry System: 6-Hydroxymethyl-1H-indazole(916902-55-1)

Safety Data

• Hazardous Substances Data: 916902-55-1(Hazardous Substances Data)

Usage

General Description

6-Hydroxymethyl-1H-indazole, also known as Indazol-6-yl-methanol, is a chemical compound with the molecular formula C8H8N2O. It is an indole derivative with a hydroxymethyl group attached to the 6-position of the indazole ring. 6-Hydroxymethyl-1H-indazole has been studied for its potential applications in organic synthesis and medicinal chemistry, as well as its role as a building block for the synthesis of various pharmaceutical compounds. It is a white crystalline powder with a molecular weight of 148.16 g/mol and has a melting point of 154-156°C. The chemical properties and applications of 6-Hydroxymethyl-1H-indazole make it a valuable compound in the field of pharmaceutical and organic chemistry.

InChI:InChI=1/C8H8N2O/c11-5-6-1-2-7-4-9-10-8(7)3-6/h1-4,11H,5H2,(H,9,10)

Upstream product

• 713-09-7 ethyl 1H-indazole-6-carboxylate 
• 2458-12-0 3-amino-p-toluic acid 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 704-91-6 1H-indazole-6-carboxylic acid 
• 724-43-6 ethyl 1-acetyl-1H-indazole-6-carboxylate 

Downstream Products

• 669050-69-5 1H-indazole-6-carboxyaldehyde 
• 152626-91-0 6-(bromomethyl)-1H-indazole 
• 944904-42-1 3-iodo-1H-indazole-6-carbaldehyde 

Relevant articles and documents

PESTICIDAL COMPOUNDS

The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, (I). The compounds of formula (I), as well as the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.